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Abstract
Background: Understanding the underlying mechanisms of neuropathic pain caused by damage to
the peripheral nervous system remains challenging and could lead to significantly improved
therapies. Disturbance of homeostasis not only occurs at the site of injury but also extends to the
spinal cord and brain involving various types of cells. Emerging data implicate neuroimmune
interaction in the initiation and maintenance of chronic pain hypersensitivity.
Results: In this study, we sought to investigate the effects of TGF-β1, a potent anti-inflammatory
cytokine, in alleviating nerve injury-induced neuropathic pain in rats. By using a well established
neuropathic pain animal model (partial ligation of the sciatic nerve), we demonstrated that
intrathecal infusion of recombinant TGF-β1 significantly attenuated nerve injury-induced
neuropathic pain. TGF-β1 treatment not only prevents development of neuropathic pain following
nerve injury, but also reverses previously established neuropathic pain conditions. The biological
outcomes of TGF-β1 in this context are attributed to its pleiotropic effects. It inhibits peripheral
nerve injury-induced spinal microgliosis, spinal microglial and astrocytic activation, and exhibits a
powerful neuroprotective effect by preventing the induction of ATF3+ neurons following nerve
ligation, consequently reducing the expression of chemokine MCP-1 in damaged neurons. TGF-β1
treatment also suppresses nerve injury-induced inflammatory response in the spinal cord, as
revealed by a reduction in cytokine expression.
Conclusion: Our findings revealed that TGF-β1 is effective in the treatment of neuropathic by
targeting both neurons and glial cells. We suggest that therapeutic agents such as TGF-β1 having
multipotent effects on different types of cells could work in synergy to regain homeostasis in local
spinal cord microenvironments, therefore contributing to attenuate neuropathic pain.
Background
Neuropathic pain caused by primary lesions in the periph-
eral nerve or by dysfunctions in the central nervous system
(CNS) has an enormous negative impact on the quality of
life of individuals affected by this condition. Unfortu-
nately, many forms of neuropathic pain cannot be ade-
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quately treated using conventional analgesics [1]; they can
only be partially managed with antidepressants and antie-
pileptics, with varying levels of success [2]. Pathogenesis
of this hypersensitive state is very complex, involving
structural, physiological and pharmacological changes
throughout the neuroaxis (from the site of peripheral
nerve injury to the spinal cord/brain). While a neuron-
centric view has dominated the literature for decades,
recent work has uncovered extensive neuroimmune inter-
actions as substrates of neuropathic pain. Interactions
between the immune and nervous systems occur at multi-
ple levels, where different types of immune/glial cells and
immune-derived substances are implicated in various
stages of pathogenesis [3].
Peripheral nerve injury can induce spinal inflammatory
reactions in the spinal cord and activation of microglia
and astrocytes [4-6]. Nerve injury-induced spinal micro-
glial activation results in activation of preexisting resident
microglia, generation of new cells [7] and recruitment of
peripheral macrophages [8]. Both resident and bone mar-
row-derived microglia are involved in the central compo-
nent of sensitization that enhances neuronal excitability.
A correlation between persistent activation of spinal astro-
cytes and chronic pain has also been established and is a
common feature of chronic pain in different animal mod-
els following peripheral nerve injury [9], spinal cord
injury [10] and bone cancer [11]. As a result of either pri-
mary injury to sensory neurons via mechanical insults or
as a secondary consequence of apoptotic cell death, dam-
aged neurons release a number of substances such as
cytokines, chemokines, excitatory amino acids and ATP,
which can in turn trigger surrounding glial activation [12].
An early, transient and robust reaction of microglia is
required for initiation of nerve injury-induced hyperalge-
sia, since they not only phagocytose cellular materials but
also produce and secrete pro-inflammatory molecules
that evoke an increase in neuronal activity of the spinal
cord dorsal horn [13]. Sustained astrocytic reaction in the
spinal cord plays an important role in maintaining neuro-
pathic pain [14]. Both activated microglia and astrocytes
are key players in the central neuroinflammation process
responsible for hyper-excitability of spinal nociceptive
neurons at different stages of pathogenesis.
The transforming growth factor (TGF)-β family members
are cytokines that fulfil key functions during development
and maintain adult tissue homeostasis. To date, three iso-
forms have been identified in mammalian tissues; TGF-
β1, TGF-β2 and TGF-β3 [15]. They act in a highly contex-
tual manner depending on the cell type and microenvi-
ronment. TGF-βs may promote cell survival or induce
apoptosis, stimulate cell proliferation or induce differen-
tiation, and their immune functions are mostly anti-
inflammatory [16]. The biological effects of TGF-βs are
transduced through the type I (RI) and type II (RII) trans-
membrane receptors. TGF-βs signalling involves binding
of the ligand to the constitutively active serine/threonine
kinase receptor RII and subsequent recruitment of RI into
a signalling complex [17]. Downstream signalling is
mediated through activation of the Smad family of pro-
teins [17], which translocate into the nucleus to regulate
gene transcription [17]. In normal adult animals, TGF-β2
and β3 are ubiquitously expressed in neurons and glia
cells in both CNS and PNS, whereas TGF-β1 is restricted
to the meninges [18]. However, up-regulation of TGF-β1
has been reported in the brains of animals with neurode-
generative disease and following ischemic injury [19].
Both in vitro and in vivo studies have illuminated the bio-
logical functions of TGF-β1 on neurons and glial cells.
TGF-β1 controls proliferation of neurons and by acting
together with other trophic factors such as GDNF, regu-
lates neuronal survival [20]. TGF-β1 blocks microglial
proliferation and free radical induction [21]. Many of the
effects of TGF-β1 on astroglia are anti-inflammatory and
immunosuppressive [16]. TGF-β1 inhibits up-regulation
of TNF-α induced by interferon-α and IL-1β [22]. TGF-β1-
/- mice that died at 3–4 weeks exhibited spontaneously
elevated iNOS expression and increased NO creation
products [23].
In the present study, we sought to determine whether
TGF-β1 can be used to alleviate neuropathic pain caused
by nerve injury. We hypothesized that through its multi-
ple effects on different types of cells, TGF-β1 could con-
tribute to restore homeostasis in a spinal cord with direct
damage to the peripheral nerve, thereby inhibiting central
sensitization and attenuating chronic hypersensitivity. By
using a well established model [24] of neuropathic pain,
we demonstrated that intrathecal infusion of recombinant
TGF-β1 was not only effective in preventing hypersensitiv-
ity following nerve injury, but also capable of reversing
thermal hyperalgesia and mechanical allodynia. The
impact of TGF-β1 on behavioural outcomes was due to its
pleiotropic effects on both neurons and glia, including
preventing neuronal damage, inhibiting spinal microglio-
sis, inhibiting spinal microglial and astrocyte activation
and reducing central inflammatory response.
Results
Intrathecal administration of TGF-β1 significantly 
attenuated nerve injury-induced hypersensitivity
To test the hypothesis that TGF-β1 alleviates behavioural
signs of neuropathic pain, we first evaluated the effects of
TGF-β1 on the development of mechanical allodynia and
thermal hyperalgesia in rats following nerve injury. Rats
started to receive TGF-β1 or saline infusion on the day of
the surgery and treatment lasted 14 days. As illustrated in
Fig 1, shortly after partial ligation of the left sciatic nerve,
rats receiving saline infusion showed an exaggerated uni-Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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lateral response to heat stimuli (Fig. 1A) and a sharp bilat-
eral decrease in response to Von Frey hair stimulation at
the plantar surface (Fig. 1B), which confirmed a similar
observation reported by Seltzer et al (1990). TGF-β1 did
not alter paw withdrawal threshold and latency in ani-
mals without injury (data not shown). However, central
infusion of TGF-β1 almost completely abolished thermal
hyperalgesia 14 days after nerve injury (89% reduction
with 5 g TGF-μβ1) (Fig. 1A). Paw withdrawal latency in
response to heat stimuli was 11.04 ± 0.93 sec (5 μg TGF-
β1) and 8.84 ± 0.18 sec (2 μg TGF-β1) vs. 5.42 ± 0.37 sec
in animals receiving saline treatment (P < 0.001 vs. saline
treated), whereas pre-surgery paw withdrawal latency was
11.51 ± 0.84 sec. Nerve injury-induced mechanical allody-
nia was reduced by 38% with a central infusion of TGF-β1
(5 μg) for 14 days (Fig. 1B). Paw withdrawal threshold on
the ipsilateral side reached 5.57 ± 0.57 g (5 μg TGF-β1)
and 5.54 ± 0.44 g (2 μg TGF-β1) vs. 1.51 ± 0.2 g (saline)
13 days following nerve injury (P < 0.001 vs. saline
treated) (Fig. 1B). There was no significant difference
between 2 μg and 5 μg doses in paw withdrawal threshold
and latency. We assume that 2 μg and 5 μg doses have
already reached the maximal effect of TGF-β1 on behavio-
ral outcomes.
Intrathecal TGF-β1 infusion prevented the development of mechanical allodynia and thermal hyperalgesia Figure 1
Intrathecal TGF-β1 infusion prevented the development of mechanical allodynia and thermal hyperalgesia. 
Shortly after partial sciatic nerve ligation, rats developed a unilateral hypersensitivity to heat stimuli (A) and a sharp bilateral 
decrease in paw withdrawal threshold in response to Von Frey hair stimulation at the plantar surface (B). Note that chronic 
intrathecal infusion of TGF-β1 (2 μg and 5 μg) started on the day of surgery for 14 days (indicated by the blue arrow) almost 
completely prevented the initiation of thermal hyperalgesia and partially attenuated mechanical allodynia (A-B). Data are 
shown as means ± SEM. **p < 0.01, ***p < 0.001, TGF-β1 treated vs saline treated at each time point, ##p < 0.01, each time 
point vs. presurgery baseline (d0) in the group of injured-saline-treated rats, n = 6 per group.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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We also examined the effects of TGF-β1 on already estab-
lished hypersensitivity following nerve lesion. Implanta-
tion of a mini-osmotic pump containing TGF-β1 (2.5 μg)
was performed on day 7 post-injury, where both paw
withdrawal threshold and latency in response to mechan-
ical and thermal stimuli, respectively, had already reached
their lowest level. Intrathecal infusion of TGF-β1 for 7
days produced a 62% reduction in established thermal
hyperalgesia (Fig. 2A) and a 28% reversal in mechanical
allodynia at ipsilateral sides (Fig. 2B). TGF-β1 also had a
slight effect on contralateral side mirror pain (Fig. 2A–B).
TGF-β1 inhibited nerve injury induced-spinal microglial 
cell proliferation
We previously reported that peripheral nerve injury
(chronic constriction of sciatic nerve with a polyethylene
tube) triggers a striking cell proliferation within the spinal
cord at the ipsilateral side of the injury. Cell proliferation
peaks at day 3 post-injury and persists at high levels at
least for 14 days, with most newly generated cells being
microglia [7]. In this study, using bromodeoxyuridine
(BrdU) as an index of DNA synthesis, we again detected a
large number of dividing cells in the lumbar spinal cord,
ipsilateral to the sciatic nerve with partial ligation (Fig
3A). The majority of BrdU-incorporated cells were micro-
Delayed administration with TGF-β1 reversed existing nociceptive behaviour Figure 2
Delayed administration with TGF-β1 reversed existing nociceptive behaviour. Rats started to receive TGF-β1 
treatment on day 7 post-surgery where both paw withdrawal latency and threshold to heat (A) and mechanical stimuli (B) 
respectively, had reached their lowest level. The 7-day infusion of recombinant TGF-β1 (2.5 μg) in the spinal cord of nerve 
injured-animals (indicated by the blue arrow) resulted in a significant increase of force (B) and latency (A) in eliciting paw with-
drawal compared to saline treated animals. *p < 0.05, **p < 0.01, ***p < 0.001, TGF-β1-treated vs. saline-treated at each time 
point, ##p < 0.01, each time point vs. presurgery baseline (d0) in the group of injured-saline-treated rats, n = 6 per group.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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TGF-β1 inhibited spinal peripheral nerve injury induced spinal microgliosis Figure 3
TGF-β1 inhibited spinal peripheral nerve injury induced spinal microgliosis. Cell proliferation evoked by peripheral 
nerve injury was evidenced by an increase in BrdU+ cells in the spinal cord, ipsilateral to the nerve lesion, which was abolished 
by TGF-β1 treatment (A). Confocal images showing colocalization of BrdU (green nucleus staining) with microglial marker Iba-
1 (red cytoplasm stain) revealed that the majority of dividing cells are microglia (B). The number of BrdU+ cells in the groups of 
animals treated or not with TGF-β1 was quantified in four different quadrants (C). Representative images of Iba-1+ cells in the 
spinal cord of naïve rats injured with saline and injured with TGF-β1 treatment depict the effects of TGF-β1 in reducing micro-
glial cell density (D); further confirmed by quantitative analysis (E). Data are shown as means ± SEM. *p < 0.05, **p < 0.01, 
TGF-β1 treated vs. saline treated in their respective region. #p < 0.05, ipsi- vs. contra-lateral sides within the same group of 
injured-saline treated rats. Scale bar: 3A) 100 μm; 3B) 20 and 10 μm; 3D) 20 μm.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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glia, as they are immunopositive for the microglial marker
ionized calcium-binding adaptor molecule 1 (Iba-1) (Fig
3B), indicating that they were newly formed microglia.
Intrathecal TGF-β1 treatment successfully inhibited spinal
microgliosis following nerve injury, as shown by a signif-
icant reduction in the number of BrdU+ cells at the ipsilat-
eral side of the spinal cord (Fig.3A, 3C), and a reduction
in density of total Iba-1+ microglial cells (Fig. 3D–E). No
significant differences were observed for two different
doses (2 μg and 5 μg) of TGF-β1, which suggests the effect
of TGF-β1 on the microglial reaction has reached the
limit.
TGF-β1 inhibited spinal microglial and astrocytic 
activation
Central TGF-β1 treatment not only inhibited generation
of new microglial cells but also prevented activation of
existing microglia. In nerve-injured rats receiving saline
treatment, there was a strong increase in Iba-1 immunore-
activity (ir) condensed at the ipsilateral side of spinal dor-
sal horn (DH) and ventral horn (VH) at 14 days post-
surgery. This pattern of microglial expression was no
longer observed in rats treated with TGF-β1 (Fig. 4A-a).
High magnification images revealed that stereotypical
changes in microglial morphology during activation were
also prevented by TGF-β1. Similar to those in normal ani-
mals, Iba-1+ cells in the spinal cord of TGF-β1-treated rats
with nerve injury had small cell bodies with long and fine
ramifications, whereas microglia in animals without TGF-
β1 treatment displayed large cell bodies and enlarged
branches following nerve injury (Fig. 4A-b). We quanti-
fied the intensity of Iba-1 immunofluorescence 14 days
after nerve injury in both groups of rats with 2 μg and 5
μg, and without TGF-β1. Both 2 μg and 5 μg TGF-β1 sig-
nificantly reduced the effects of nerve injury on Iba-1 ir at
the ipsilateral sides DH and VH, with the exception of 2
μg TGF-β1 on the ventral horn, where the effect was not
statistically significant (Fig. 4B). We also quantitatively
evaluated the effects of TGF-β1 on Iba-1 protein levels at
day 7 post-injury with Western Blot. Seven days after
nerve injury, the quantity of Iba-1 protein at the ipsilateral
side was 1.48 times higher than their contralateral coun-
terpart. Infusion of 1 μg TGF-β1 for one week, similar to
the paradigm we used for immunohistochemistry and
behavioural studies with 2 μg TGF-β1 infusion for two
weeks, significantly reduced the difference between ipsi
and contralateral dorsal horns to 1.1 times (Fig. 4C–D).
Next, we examined the effects of TGF-β1 on astrocyte acti-
vation in the spinal cord following nerve injury. Spinal
astrocytes were labelled with an antibody against glial
fibrillary acid protein (GFAP). Changes in GFAP ir and in
the morphology of astrocytes within the spinal cord after
peripheral nerve injury are depicted in Fig 5A. Partial liga-
tion of sciatic nerve dramatically increased GFAP ir and
altered the morphology of astrocytes with enlarged
branches at the ipsilateral side of the spinal cord (Fig. 5A,
top panels). These effects were attenuated by TGF-β1 in a
dose-dependent manner (Fig. 5A–B, middle and lower
panels). Treatment with TGF-β1 at 2 μg for 14 days
reduced the effect of nerve injury on GFAP ir by 13.9% in
DH and 12.3% in VH, whereas at 5 μg TGF-β1 decreased
the up-regulation of GFAP ir by 43.1% in DH and 49.12%
in VH (Fig. 5A–B), showing a higher dose (5 μg) is more
effective in astrocytic response.
TGF-β1 protected neurons from damage following 
peripheral nerve injury
Partial sciatic nerve ligation induced the expression of
activating transcription factor 3 (ATF3) in the nucleus of
sensory neurons in the dorsal root ganglia (DRG) and in
the nucleus of motor neurons in the spinal cord (Fig. 6A–
C). The number of ATF3+ neurons in the spinal cord was
remarkably reduced by 2-week intrathecal TGF-β1 infu-
sion starting on the day of surgery. Fourteen days after sci-
atic nerve injury, in the ipsilateral side ventral horn, there
were 9.36 ± 0.96 ATF3+ cells in the group of rats infused
with saline, whereas in rats treated with 2 μg TGF-β1, there
were only 3.22 ± 0.15 (2 μg) ATF3+ cells. Fourteen days
after sciatic nerve injury, there were 9.36 ± 0.96 ATF3+ cells
on the ipsilateral side ventral horn in saline-treated group,
whereas in rats treated with 2 μg TGF-β1, there were only
3.22 ± 0.15 ATF3+ cells (Fig. 6D). Although TGF-β1 was
introduced intrathecally, expression of ATF3 in the ipsilat-
eral DRG was also affected; 4.2 ± 0.5 ATF3+ cells in saline
treated rats vs. 1.00 ± 0.09 ATF3+ cells in TGF-β1 treated
rats (Fig. 6E).
As we have previously reported that damaged ATF3+ neu-
rons express chemokine MCP-1 [9] which is a trigger for
surrounding microglial activation [8], we further investi-
gated the regulation of MCP-1 expression by TGF-β1. Sim-
ilar to that of ATF3 regulation, both in the spinal cord
ventral horn and in the ipsilateral DRG, the number of
MCP-1+ neurons and the intensity of MCP-1 imunoreac-
tivity was significant lower in rats treated with TGF-β1
than those treated with saline (Fig. 6F).
TGF-β1 reduced spinal inflammatory response following 
peripheral nerve injury
The role of nerve injury-induced spinal inflammation in
the initiation and maintenance of chronic pain has been
well documented. To explore whether TGF-β1, a potent
anti-inflammatory cytokine, could alter local inflamma-
tory response and thereby explain its potential effect on
hypersensitivity, we measured levels of pro-inflammatory
cytokines Il-1β, TNF-α and IL-6 transcripts in the spinal
cord with quantitative real time-PCR. Relative mRNA lev-
els were normalized with the average of three housekeep-
ing genes (atp5o, Hprt1, G6pdx). Fold changes relative toMolecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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naïve spinal cord were determined using comparative Ct
method [25] and is depicted in Figure 7. Expression levels
of IL-1β and IL-6, but not of TNF-α, increased dramati-
cally at the ipsilateral spinal cord following nerve injury.
These effects were significantly reduced by TGF-β1 treat-
ment (Fig. 7).
Expression of TGF-β1, TGF-β1 receptor and the signal 
transducers Smads in the spinal cord following nerve injury
To gain insight into the potential mechanisms of the plei-
otropic effects of TGF-β1 in this specific neuropathic con-
dition, we examined the expression of endogenous TGF-
β1, the cellular localization of its receptors-TGFβRI/II and
the phosphorylation states of receptor-regulated Smad2/
3, as well as the expression of the common mediator
Smad 4. By using in situ hybridization method, TGF-β1
mRNA was not detected within the spinal cord of animals
suffering nerve injury from day 0 (naïve) to day 14 (Fig.
8A). Western Blot analysis revealed that endogenous TGF-
β1 protein was not detectable in the spinal cord of rats fol-
lowing nerve injury. However, chronic intrathecal infu-
sion of recombinant TGF-β1 resulted in a stable and
similar level of the protein at both dorsal and ventral
horns (Fig. 8B). This expression pattern confirms that the
pleiotropic cellular effects of TGF-β1 and the subsequent
impact on behavioural outcomes are essentially mediated
through exogenous TGF-β1, excluding the interference of
endogenous TGF-β1.
TGFβRI mRNA was up-regulated in the spinal cord and
DRG, ipsilateral to the nerve injury (Fig. 8C). Positive sig-
nals (silver grains) for TGFβRI mRNA were observed on
the ventral horn motor neurons and DRG sensory neu-
rons (identified based on the position, appearance and
size of cells) and on some glial cells in both dorsal and
ventral horns, which were heavily stained with thionine
(Fig. 8C). TGFβRII mRNA was not detected by in situ
hybridization within the spinal cord parenchyma follow-
ing nerve injury but was found in the plexus and ventricle
in the normal brain (data not shown).
The binding of ligand TGF-β1 to a heteromeric receptor
complex consisting of TGFβRI and TGFβRII, leads to acti-
vation of the Smads signalling pathway, including recep-
tor-regulated Smads (R-Smads)-Smad2/3 and the
common mediator (Co-Smad)-Smad 4. This intracellular
cascade is critical to the pleiotropic action of TGF-β1
superfamily responses. To determine whether Smad sig-
nalling was activated in the spinal cord of rats with nerve
injury following TGF-β1 challenge, we measured protein
levels of phosphorylated Smad 2/3 and Smad 4 in the spi-
nal cord with Western Blot. Both p-Smad 2/3 (Fig. 8D)
and Smad 4 (Fig. 8E) were up-regulated at the ipsilateral
spinal cord after TGF-β1 treatment.
Discussion
Peripheral nerve injury produced a long lasting mechani-
cal allodynia and thermal hyperalgesia. This hypersensi-
tive state was accompanied by early and robust spinal
microglial reaction, including a striking spinal microglio-
sis, persistent spinal astrocyte activation and a spinal
inflammatory reaction, evidenced by an increase in proin-
flammatory cytokine levels. We investigated the effects of
anti-inflammatory cytokine TGF-β1 delivered intrathe-
cally on neuropathic pain behaviour. Our findings dem-
onstrate that TGF-β1 is effective, not only in preventing,
but also in reversing the hypersensitivity evoked by dam-
age to the peripheral nerve. Three salient features of TGF-
β1 were observed in this study: 1) TGF-β1 exerts potent
neuroprotective effects that minimize neuronal damage
following peripheral nerve injury; 2) TGF-β1 inhibits spi-
nal microglial and astrocytic activation; and 3) TGF-β1
decreases nerve lesion induced up-regulation of pro-
inflammatory cytokine IL-1β and IL-6 within the spinal
cord.
Although it has been reported that TGF-β1 could trigger
neuronal cell death [26,27], numerous in vitro and in vivo
studies have shown a protective effect of TGF-β1 against
various toxins and injurious agents [18,28]. TGF-β1 pre-
vented neuronal damage when delivered intracerebrally
or using viral vectors into rodent brains after ischemic
insults [28]. TGF-β1 may have similar effects in neurode-
Role of TGF-β1 in mediating spinal microglial reaction Figure 4 (see previous page)
Role of TGF-β1 in mediating spinal microglial reaction. A-a: Photomicrographs depicting Iba-1 staining in L5 spinal 
cord section 14 days after nerve injury. To compare with naïve rats, partial sciatic nerve ligation induced a striking increase of 
immunoreactivity at the ipsilateral side DH and VH. This increase was almost completely abolished in TGF-β1 treated animals. 
A-b: High magnification confocal images demonstrate morphological changes in resting and activated microglia and the effects 
of TGF-β1 on microglial activation. B: Intensity of Iba-1 immunofluorescence determined as average pixel intensity on specific 
area of interest on L5 section at 14 days after injury. C-D: Western Blot analysis demonstrating that up-regulation of Iba-1 
protein at the ispilateral side spinal cord was inhibited by TGF-β1 infusion. Tissue samples were collected at 7 days post-injury. 
Data are shown as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, TGF-β1 treated vs. saline treated in their respective 
region. ###p < 0.001, ##p < 0.01, ipsi- vs. contra-lateral sides within the same group of injured-saline treated rats. Scale bar: 
A-a) 1 mm, A-b) 10 μm.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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generative diseases such as Alzheimer's disease and Par-
kinson's disease [29-31]. The roles of TGF-β1 in
maintaining neuronal integrity and survival were also evi-
denced with molecular approaches. TGF-β1-/-  mice
showed increased numbers of apoptotic neurons, reduc-
tion in neocortical presynaptic integrity, and died at the
age of 3–4 weeks [32]. Heterozygous knock out (TGF-β1-/
+) mice showed increased susceptibility to excitotoxic
injury and neurodegeneration, whereas transgenic over-
expression of TGF-β1 prevented degeneration after excito-
toxic injury [32]. ATF3 is a member of the activating tran-
scription factor/cAMP-responsive element binding
protein family (ATF/CREB family) and is recognized as a
useful marker for nerve injury. It is detected in DRG sen-
sory neurons and spinal cord motor neurons within hours
of axotomy [33] and lasts for at least 80 days post-injury
Role of TGF-β1 in mediating spinal astrocytic reaction Figure 5
Role of TGF-β1 in mediating spinal astrocytic reaction. A: Peripheral nerve injury induced an astrocytic activation at 
the ipsilateral side DH and VH evidenced by an increase of GFAP immunoreactivity. 5 μg TGF-β1 infusion for 14 days signifi-
cantly reduced the increase in GFAP ir, whereas the effect of 2 μg TGF-β1 was negligible. B: Intensity of GFAP signal deter-
mined as average pixel intensity at specific area of interests on L5 section at 14 days after injury. Data are shown as means ± 
SEM. *p < 0.05, ***p < 0.001, TGF-β1 treated vs. saline treated in their respective region. ###p < 0.001, ipsi- vs. contra-lateral 
sides within the same group. Scale bar: 100 μm.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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Neuroprotective effects of TGF-β1 Figure 6
Neuroprotective effects of TGF-β1. Partial sciatic nerve ligation caused neuronal damage to both ipsilateral side ventral 
horn (VHi) motor neurons (A-B) and ipsilateral side DRG (DRGi) sensory neurons (C), in which ATF3 expression was 
induced. TGF-β1 treatment prevented neuronal damage by reducing the numbers of ATF3+ cells within the spinal cord and 
DRG (A-E). TGF-β1 treatment also reduced the expression of MCP-1 on VHi and DRGi. Note that both the number of MCP-
1+ cells and the intensity of MCP-1 ir were significantly reduced by TGF-β1 (F). Data are shown as means ± SEM. *p < 0.05, 
TGF-β1 treated vs. saline treated in their respective region. Scale bar: A) 200 μm, B-C) 100 μm, F) 50 μm.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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[34]. In this study, recombinant TGF-β1 delivered into the
spinal cord significantly reduced the number of ATF3+
cells. This is consistent with previous findings showing
neuroprotective effects of this cytokine, which could be a
direct pathway in restoring neuronal damage resulting
from nerve injury. TGF-β1 delivered into the spinal cord
not only protected spinal motor neurons but also sensory
neurons in DRG following a partial ligation on the sciatic
nerve. This finding further confirms that intrathecal injec-
tion is an effective delivery method for drugs that interfere
with the expression and function of target genes in both
peripheral sensory ganglia and their postsynaptic targets
in the spinal cord [35]. Different mechanisms have been
postulated to explain how TGF-β1 protects neurons
against injury and degeneration. A particularly striking
example is the interaction of TGF-β1 with some other neu-
rotrophins. TGF-β1 may synergize with these neuro-
trophins by dramatically increasing their potency or they
may be required to mediate at least some of the effects of
NGF, BDNF and NT-3, as well as FGF-2 and GDNF [20].
However, in this specific case where exogenous TGF-β1
significantly improved the nerve injury induced neuro-
pathic pain, whether and how TGF-β1 interacted with
other trophic factors is not clear and further studies are
needed for clarification. The detection of TGFβRI mRNA
on neurons indicates that TGFβ-1 alleviates neuropathic
pain at least partially through direct action on damaged
neurons.
TGF-β1 could also act directly on the CNS glial cells. Sev-
eral lines of evidence support the notion of TGFβ-1 is a
suppressor of functions of activated microglia. TGF-β1
inhibits proliferation of microglia and blocks free radical
induction [21,36]. Moreover, TGF-β1 selectively induces
apoptosis of microglia through a Bcl-2 independent
mechanism [36]. In most situations, TGF-β1 inhibits
growth of astrocytes and affects their morphology and
mobility [37,38]. Recent studies in knock-out mice dem-
onstrated that deficiency in TGF-β1 caused gliotic changes
throughout the CNS, affecting astrocytes, microglia and
perivascular macrophages [39]. These changes include
increases in GFAP-ir, two to three-fold expansion in the
number of perivascular macrophages with a strong immu-
noreactivity for MHCII, and a proliferation of microglia
that express a panel of phagocytic inflammatory markers
[39]. Transection of the facial nerve in TGF-β1-/- provoked
a more pronounced astrogliosis and a dramatic increase in
phagocytosis-related microglial markers including Iba-1
[39]. Results from our investigations clearly demonstrate
that injury to the sciatic nerve induced a persistent hyper-
sensitivity of the paw accompanied by spinal microglial
and astrocytic activation and that TGF-β1 treatment atten-
Anti-inflammatory effects of TGF-β1 Figure 7
Anti-inflammatory effects of TGF-β1. The expression of proinflammatory cytokines IL-1β, TNF-α and IL-6 in rat lumbar 
spinal cords was measured by real time quantitative PCR. Peripheral nerve injury created an inflammatory reaction within the 
spinal cord by increasing levels of IL-1β and IL-6 but not TNF-α at the ipsilateral side. TGF-β1 significantly inhibited inflamma-
tory response by reducing the increase of IL-1β and IL-6 expression. Data are shown as means ± SEM. ###p < 0.001, ipsilateral 
side vs. contralateral side; * p < 0.05, **p < 0.01, TGF-β1 treated vs. saline treated in their respective region.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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Figure 8 (see legend on next page)Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
Page 13 of 18
(page number not for citation purposes)
uated or abolished the microgliosis and activation of
microglia and astrocytes following nerve injury. Inhibi-
tory effects of TGF-β1 on microglia and astrocytes could
occur by directly targeting spinal glial cells where the
TGFβ type I receptor was detected. This could also be pos-
sible through indirect pathway via protection of neuronal
damage. Our previous results revealed that, following sci-
atic nerve injury, damaged ATF3+ DRG sensory neurons
and spinal cord motor neurons were induced to express
chemokine MCP-1 [9]. Neuronal MCP-1 is critical for
both resident spinal microglial activation and peripheral
macrophage infiltration and in the development of neuro-
pathic pain [8]. Our current results further confirmed that
reducing the numbers of ATF3+ neurons by TGF-β1 also
reduced the production of MCP-1. These findings suggest
that in addition to direct action on glial cells, TGF-β1
could attenuate neuropathic pain by suppressing neuro-
nal MCP-1 expression, consequently inhibiting neuron-
glia signalling.
CNS glial cells are considered immune-competent cells.
Immediately following injury directly to the CNS or
remotely to the PNS, damage-sensing glial cells become
locally activated and release inflammatory mediators to
defend against potential invading pathogens. Several
proinflammatory cytokines and chemokines have been
implicated in altered nociceptive processing via direct
action on primary afferent neurons or through indirect
activation of signalling pathways in immune/glial cells,
resulting in an excitatory positive feedback loop in the
pain pathway. It has been recently demonstrated that
TNF-α and IL-6 modulate excitatory and inhibitory synap-
tic transmission respectively, whereas IL-1β controls both
excitatory and inhibitory synaptic transmission [40]. Spi-
nal IL-1β was also shown to induce the transcription of
pronociceptive genes such as COX-2 in the spinal cord
[41]. All three proinflammatory cytokines induced phos-
phorylation of the transcription factor CREB, which is
essential to the maintenance of long-term neural plasticity
in dorsal horn neurons [42]. By using real time PCR, we
observed a significant increase in IL-1β and IL-6 gene
expression at the ipsilateral side of the spinal cord.
Although the increase of TNF-α transcript within the spi-
nal cord was not detected, one cannot exclude the possi-
bility that up-regulation of TNF-α gene expression
occurred in the DRG and the protein was then transported
into the central terminals. We speculate that local spinal
inflammation enhances central sensitization and is criti-
cal to the development of neuropathic pain. Our data
strongly suggest that exogenous TGF-β1 mitigates neuro-
pathic pain through inhibition of the production of pro-
inflammatory cytokines.
TGF-β1 uses a well-characterized signal transduction
pathway that extends from the cell membrane to the
nucleus. Active TGF-β1 ligand binds to TGFβRII to form a
complex with TGFβRI. Activation of a receptor complex
leads to phosphorylation of Smads proteins. Thus, expres-
sion of both receptors is required for TGFβ-1 signalling.
However, in in vivo conditions, parallel regulation of the
ligand and their receptors and co-expression of two recep-
tor subtypes on the same cell are not always seen. By using
in situ hybridization, we detected expression of TGFβRI in
both neurons and glial cells at the ipsilateral side lumber
spinal cord without the presence of TGFβRII. One possi-
ble interpretation is that TGFβRII, which is often constitu-
tively active [17], could be present at levels undetectable
by the method used in this study; however, it remained
functional. This idea is supported by our results on
Smad2/3 and Smad4. Peripheral nerve damage altered
spinal cord homeostasis, affecting both neurons and glia;
and exogenous TGF-β1 activated the signalling pathway
(TGFβRI/TGFβRII receptor complex and Smad) and there-
fore contributed to alleviating chronic pain through its
pleiotropic effects on different types of cells.
Our study is the first demonstration of the significant
impact of TGF-β1 in normalizing behavioural pain and
other changes associated with neuropathic pain states.
Pleiotropic effects of TGF-β1 are sufficient to prevent
onset of abnormal pain states arising from the neuropa-
thy. In addition, a delayed treatment paradigm in which
TGF-β1 administration began after the establishment of
neuronal damage, glial activation and local inflammatory
Expression of TGF-β1, its receptor and signalling proteins-Smads in the spinal cord and DRG Figure 8 (see previous page)
Expression of TGF-β1, its receptor and signalling proteins-Smads in the spinal cord and DRG. A: The expression 
of endogenous TGF-β1 mRNA was not detected by in situ hybridization at different time points after nerve injury. B: Endog-
enous TGF-β1 protein within the spinal cord was not found by Western Blot, however, intrathecal infusion of recombinant 
TGF-β1 for 14 days resulted in a stable level in both spinal cord ventral and dorsal horns. C: Expression of TGF-β type I recep-
tor (TGF-βRI) mRNA was observed in the spinal cord and DRG. High magnification microscopic analysis revealed that positive 
signals (silver grains) for TGFβRI mRNA were located on both ventral horn motor neurons and DRG sensory neurons (identi-
fied based on the position, appearance and size of cells, encircled in blue), and on some glial cells in both dorsal and ventral 
horns that were heavily stained with thionine. D-E: Recombinant TGF-β1 induced phosphorylation of Smad 2/3 (pSmad2/3) 
(D) and up-regulated the total level of Smad 4 in the spinal cord. Tissue samples were collected 7 days post-injury and TGF-β1 
infusion. Data are shown as means ± SEM. **p < 0.01, ***p < 0.001, TGF-β1 treated vs. saline treated in their respective region.Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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reaction, demonstrated that TGF-β1 can indeed reverse
neuropathic pain. In clinical settings, drug treatment is
initiated after onset of neuropathic pain. Therefore, the
ability of an agent to reverse established pain may trans-
late into clinical usefulness. Although it is well known
that TGF-β1 is a pleiotropic protein, our results clearly
demonstrate that its pleiotropic role can have a positive
impact in spinal cord homeostasis and on hypersensitivity
following nerve injury, where the pathology is a result of
dysfunction at different cellular levels. Functional
improvements may be attributed to the ability of TGF-β1,
acting as a multipotent cytokine, to support neuronal sur-
vival, modulate inflammatory response and orchestrate
neuronal and glial response to injury. The efficacy of exog-
enous TGF-β1 in blocking nerve injury-induced pain elic-
its TGF-β1 as a potential therapeutic agent for neuropathic
pain. Consequently, due to the pleiotropic effects of TGF-
β1, a detailed investigation of the off-target side effects is
necessary to validate TGF-β1 as a therapeutic agent.
Methods
Animals
Adult male Sprague-Dawley rats (Charles River, Quebec,
Canada) were used and weighed 250–275 g at time of sur-
gery. Before surgery, they were acclimatized to standard
laboratory conditions (14-h light, 10-h dark cycle) and
given free access to rat chow and water. All protocols were
performed in accordance with guidelines from the Cana-
dian Council on Animal Care and were approved by the
McGill University Animal care Committee.
Nerve injury and behavioural studies
Peripheral nerve injury
Rats were anaesthetized with a mixture of ketamine and
xylazine (100 mg/kg body weight, i.p.). The left common
sciatic nerve was exposed via blunt dissection through the
biceps femoris muscle. The nerve was isolated from sur-
rounding connective tissue and approximately 4–6 mm of
the nerve was elevated minimally and partial sciatic nerve
ligation was conducted according to the method
described by Seltzer et al. [24]. Briefly, the dorsum of the
nerve was carefully freed from surrounding connective tis-
sues at a site near the trochanter. A 6-0 suture was inserted
into the nerve with a 3/8 curved, reversed-cutting mini-
needle (Tyco Health Care, Mississauga, Ontario, Canada)
and tightly ligated so that the dorsal one-third to one-half
of the nerve thickness was trapped in the ligature. The
muscle and skin layers were closed under aseptic condi-
tions with two muscle sutures (4-0) and three to four skin
sutures (4-0). Sham-operated rats underwent the same
surgical procedure but the nerve was exposed and left
intact. Survival times were 7 and 14 days post-surgery. A
group of naive rats was included in the protocol to obtain
basal levels of certain gene and protein expression.
Behavioural analysis
Animals were habituated to the testing environment daily
for at least two days before baseline testing. All animals
were assessed for mechanical allodynia and thermal
hyperalgesia of both hind paws before surgery and from
days 2–3 after injury until they were killed for histological
studies. The investigator was totally blinded to the treat-
ments the rats received. Mechanical sensitivity was
assessed using calibrated von Frey Hairs as described by
Chaplan et al [43]. Animals were placed in boxes on an
elevated metal mesh floor and allowed 40 to 60 min for
habituation before testing. A series of von Frey filaments
with logarithmically incrementing stiffness (Stoelting)
was applied perpendicular to the mid-plantar region of
the hind paw. The 50% paw withdrawal threshold was
determined using Dixon's up-down method as previously
described [44]. Thermal hyperalgesia was measured using
paw withdrawal test. Animals were placed on a glass floor
within Plexiglass cubicles. After habituation, a focused
high-intensity projector lamp was directed below onto the
mid-plantar surface of the hind paw and reaction time
(withdrawal latency of the hind paw) of the rat was
recorded automatically [45]. The commercial device (IITC
Model 336) was calibrated so that the pre-surgical base-
line paw withdrawal latencies were approximately 10–12
seconds. Twenty seconds was used as a cut-off time to
avoid damage to the animal's skin. The measurements
were repeated four times, at 3 min intervals on each paw,
and the initial pair of measurements was not used. The
average of the three remaining pairs of measurements was
taken as data. Efficacy of TGF-β1 was determined accord-
ing to the following formula: MeanTGF-β1-Meancon-
trol(saline)/Meannaive(baseline)-Meancontrol(saline) × 100%.
TGF-β1 administration
Rat recombinant TGF-β1 (Peprotech, RockyHill, New Jer-
sey, U.S.A.) was delivered into nerve injured and sham-
operated rats with an intrathecal catheter driven by a
mini-osmotic pump (Alzet, Palo Alta, CA). The catheter
and pump were implanted according to the procedure
originally described for chronic catheterization of the rat
spinal cord [46]. Animals were anaesthetized with a mix-
ture of ketamine/xylazine (100 mg/kg, intraperitoneally).
A midline incision was made to expose the atlanto-occip-
ital membrane. The membrane was pierced and the cath-
eter was passed intrathecally to a distance of 8.5 cm, i.e.,
caudal to the level of the atlanto-occipital junction. The
coiled part of the system with the pump attached was then
implanted subcutaneously in a pouch to lie behind the
shoulders. Rats showing any signs of motor impairment
were excluded from the protocol. Alzet osmotic mini-
pumps were filled with 0.9% saline or TGF-β1 and primed
in a 37°C bath over night. All intrathecal tubings and
pumps were verified at the end of experiments during tis-
sue collection. Animals having a defective intrathecalMolecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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catheterization (either disconnected or clogged) were
eliminated from the study.
TGF-β1 treatment paradigms
Experiment 1
Intrathecal catheters and osmotic pumps were implanted
at the time of nerve ligation surgery to determine the
impact of TGF-β1 on the development of neuropathic
pain. Rats received saline or TGF-β1 treatment (2 μg and
5 μg, respectively with Alzet pumps 2002D) for 14 days
(day 0–14) (n = 6 per group). In our pilot study with 0.5–
1  μg TGF-β1 infusion, we observed partial effects on
behavioural and microglia response (data not shown). To
examine whether this is the maximal effect, we increased
the dose of TGF-β1 to 2 μg and 5 μg. Animals were per-
fused at day 14 post-injury and treatment for histological
analysis. In another group, rats received saline or TGF-β1
infusion (1 μg with Alzet pumps 1007D) for 7 days (day
0–7) (n = 6 for saline and n = 12 for TGF-β1 infusion). Tis-
sues collected from this group of rats were subjected to
real-time quantitative PCR and Western Blot analysis.
Naïve and Sham operated rats (n = 3 per group) were also
included in the protocol.
Experiment 2
To determine whether TGF-β1 could also reverse already
established neuropathic hypersensitivity, TGF-β1 (2.5 μg
using Alzet pumps 1007D) was delivered intrathecally
starting from day 7 post-injury, when both mechanical
allodynia and hyperalgesia had reached their lowest level.
Treatment lasted for 7 days (day 7–14) (n = 3 for saline
and n = 4 for TGF-β1 infusion).
Tissue preparation
For histological studies
Rats were deeply anaesthetized with ketamine/xylazine
and then perfused transcardially with 0.9% saline fol-
lowed by 4% paraformaldehyde (PFA) in 0.1 M sodium
phosphate buffer (pH 7.4). Lumbar spinal cords and L4–
L6 dorsal root ganglia (DRG) were removed and placed in
the same fixative overnight, then transferred to 30%
sucrose for cryoprotection. Frozen spinal cords and DRG
were cut transversely into 30-μm-thick sections on a slid-
ing microtome, collected in an anti-freeze solution [0.05
M sodium phosphate buffer (pH 7.3) containing 30%
ethylene glycol and 20% glycerol] and stored at -20°C
until use.
For real time PCR experiments
Rats were deeply anaesthetized with isoflurane and deca-
pitulated, then lumbar spinal cords were quickly removed
and dissected into ipsilateral and contralateral portions
and then snap frozen in liquid nitrogen and stored at -
80°C until use.
For Western Blot studies
Animals were transcardially perfused with Ringer Solution
and lumbar spinal cords were removed and dissected into
quadrants of 1) ipsilateral dorsal horn (DHi), 2) contral-
ateral dorsal horn (DHc), 3) ipsilateral ventral horn
(VHi), and 4) contralateral ventral horn (VHc), and then
frozen in liquid nitrogen stored at -80°C until use.
Cell proliferation study
The thymidine analog bromodeoxyuridine (BrdU) was
used to label proliferating cells in the spinal cord after sci-
atic nerve injury. BrdU was injected intraperitoneally (100
mg/Kg body weight) at day 3 post-injury; the time when
peripheral nerve injury-induced cell proliferation within
the spinal cord reached its peak [7]. Animals were per-
fused transcardially with 4% paraformaldehyde (PFA) for
tissue collection. To allow for detection of cells incorpo-
rated with BrdU, free-floating sections were pre-treated
with 50% formamide in 2 × SSC for 2 h at 65°C, followed
by 15 min in 2 × SSC at room temperature, and 30 min in
2N HCl at 37°C for 10 min in 0.1 M borate buffer at room
temperature. A polyclonal goat anti-rat antibody against
BrdU (1:250; Accurate Chemicals, Westbury, NY) was
incubated with tissue sections for 48 h at 4°C. After pri-
mary antibody incubation, sections were incubated in
Alexa 488-conjugated goat anti-rat IgG (1:250; Invitrogen,
Carlsbad, CA) for 1 h. Sections were mounted onto slides
and coverslipped with Vectashield mounting medium
(Vector Laboratories, Burlingame, CA).
Immunohistochemistry
Regular immunofluorescent staining was performed to
characterize the spinal glial cell reaction to peripheral
nerve injury and to TGF-β1 chronic infusion. Free-floating
sections were incubated overnight at 4°C with the follow-
ing antibodies: rabbit anti-ionized calcium-binding adap-
tor molecule 1 (Iba-1) polyclonal antibody (for microglia
and macrophages, 1:1000; Wako Chemicals, Richmond,
VA); and rabbit anti-glial fibrillary acid protein (GFAP)
polyclonal antibody (for astrocytes, 1:1000; DakoCyto-
mation, Carpinteria, CA); followed by a 60-min incuba-
tion at room temperature in fluorochrome-conjugated
goat secondary antibody. 4',6-Diamidino-2-phenylindole
dihydrochloride (Dapi) was also used as a nuclear coun-
terstain (1:10000, Sigma).
Some spinal cord and DRG sections were processed by
avidin-biotin method using peroxidase as a substrate to
detect damaged neurons labelled by antibodies against
activating transcription factor 3 (ATF3) and monocyte
chemoattractant protein-1 (MCP-1). Briefly, sections were
rinsed with TBS and incubated with goat anti-rabbit ATF3
antibody (1:500, Santa Cruz biotechnology, USA,) or goat
anti-rabbit MCP-1 antibody (1:2000, Peprotech, Rocky-
Hill, New Jersey, U.S.A) over night at 4°C and incubatedMolecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
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sequentially with a biotinylated secondary antibody (Vec-
tor Laboratories, Canada), followed by an avidin-biotin-
peroxidase complex (Vectostain ABC Elite Kit, Vector Lab-
oratories). After several washes in TBS, tissue sections were
reacted in 0.05% diaminobenzidine and 0.003% hydro-
gen peroxide and some sections were counterstained with
thionin.
In situ hybridization
Detection of mRNAs encoding TGF-β1, TGFβRI and TGF-
βRII was performed on lumbar spinal cord and DRG sec-
tions using 35S-labeled riboprobes. Riboprobe synthesis
and hybridization were performed as per a previously
described protocol [47]. Briefly, plasmids were linearized
and sense and anti-sense cRNA probes were synthesized
with appropriate RNA polymerase as described in Table 1.
Sections were postfixed in 4% PFA and digested by protei-
nase K (10 μg/ml, at 37°C for 20 min), after which spinal
cord sections were rinsed in water and by a solution of 0.1
M triethanolamine (TEA, pH 8.0), acetylated in 0.25%
acetic anhydride in 0.1 M TEA and then dehydrated.
Hybridization of the sections by riboprobe involved a 106
cpm/ml/slide of hybridization mixture and incubation at
55°C overnight in a slide warmer. Slides were rinsed in
standard saline citrate (1 × SSC: 0.15 M NaCl, 15 mM
trisodium citrate buffer, pH 7.0) and digested by RNase A
at 37°C (20 μg/ml), rinsed in descending concentrations
of SSC, and dehydrated through graded concentrations of
ethanol. Sections were exposed to x-ray film (BioMax,
Kodak, Rochester, NY) for 2–3 days and dipped in NTB2
nuclear emulsion (diluted 1:1 with distilled water,
Kodak). Slides were kept at 4°C for 3–5 weeks safe from
light and developed in D19 developer (Kodak).
Western Blot Analysis
Tissues were homogenized in a lysis buffer containing a
cocktail of proteinase and phosphatase inhibitors (Roche,
Indianapolis, USA). Protein concentrations were deter-
mined by BCA Protein Assay (Pierce) and 15 μg of pro-
teins were loaded and separated on SDS-PAGE gel (12%).
After the transfer, blots were incubated overnight at 4°C
with the following antibodies as per manufacturer's
instructions: goat anti-p-Smad2/3 (1:500, Santa Cruz);
goat anti-Smad4 (1:250, Santa Cruz); rabbit anti-Iba-1
(1:500, Wako); and goat anti-TGF-β1 (1:500, Santa Cruz).
For loading control, blots were probed with β-actin anti-
body (1:10000, Sigma). Density of specific bands from
Western Blotting was quantified with a computer-assisted
imaging analysis system (Image Pro Plus).
RNA extraction and real-time quantitative PCR
Total RNA was extracted from spinal cords using Qiazol
(Invitrogen) followed by digestion with RQ1 RNase-Free
DNase RNeasy kit (Qiagen) to remove DNA contamina-
tion. Synthesis of cDNA from total RNA was performed
with SuperScript II Reverse Transcriptase (Invitrogen).
Primers (see Table 2) were chosen using the GeneTools
software (Biotools Inc.) and their specificity was verified
using the GenBank database from the NCBI website.
Nineteen samples were analysed (5 TGF-β1-treated ani-
mals; 3 saline-treated animals; 3 naive animals). Experi-
ments were performed in duplicate using the LightCycler
480 Real-Time PCR Detection System (Roche Diagnos-
tics). Levels of target mRNAs were normalized to the aver-
age of the three housekeeping genes; Atp50, Hpt1 and
G6pdx. Fold changes versus naive animals in their respec-
tive ipsi and contralateral sides were analyzed using the
comparative Ct (dCT) method [25].
Image processing and analysis
Images were acquired using either an Olympus BX51
(Tokyo, Japan) microscope equipped with a colour digital
camera (Olympus DP71) or an Olympus confocal laser-
scanning biological microscope (Fluoview 1000). Colo-
calization was ensured with confocal Z stacks at 0.8 μm
intervals and visualization in three-dimensional orthogo-
nal planes. Quantitative analysis of the immunofluores-
cence intensity was performed on images digitized using a
constant set of parameters (exposure time, gain, and post-
image processing) with special attention to avoid signal
saturation. We measured the intensity of Iba-1 and GFAP
immunofluorescence as the average fluorescence intensity
within four areas of interest (AOI) defined as: 2 rectangles
(100 × 300 μm/each) on the dorsal horn (DH) (lamina I–
IV) and 2 rectangles (261 × 370 μm/each) on the ventral
horn (VH) (lamina IX), on both sides relative to the side
of injury. Fluorescence intensity was measured using
Image Pro Plus 6.2 for Windows (Media Cybernetics Inc.).
The total number of BrdU+ cells and Iba-1+ microglial cells
was counted by blinded investigators in four different
regions: ipsilateral DH (DHi), contralateral DH (DHc),
VHi, and VHc. Only uniformly BrdU+-labelled nuclei and
Iba-1+ cells showing a positive nucleus stained with Dapi
were considered for quantification. Samples from 4–6 sec-
Table 1: Plasmids and enzymes used for synthesis of the cDNA probes
Plasmid Vector Insert Antisense probe Sense probe GenBank Reference
Topo+TGFβRI BluntIItopo 597 pb Pst1/Sp6 HindIII/T7 NM-009370
Topo+TGFβRII BluntIItopo 592 pb BamHI/T7 XbaI/Sp6 D32072
pBSKS+ TGF-β1 pBSKS+ 1,173 pb EcorI/T3 XhoI/T7 BC013738Molecular Pain 2009, 5:16 http://www.molecularpain.com/content/5/1/16
Page 17 of 18
(page number not for citation purposes)
tions per rat and 6 rats per group were included for each
quantitative analysis.
Statistical analysis
All data are presented as means ± SEM. Statistic signifi-
cance was determined using: 1) for behavioural analysis
in Fig 1 and Fig 2, one way ANOVA followed by Dunnet's
test for the changes of all time points vs. pre-surgery base-
line; unpaired t-test for the difference between groups
(TGF-β1-treated vs. saline-treated at each time point); 2)
paired t-test for the difference between ipsi- and contra-
lateral sides within the same group; and 3) unpaired t-test
for the difference between groups (TGF-β1-treated vs.
saline-treated in their respectively DH and VH region. The
criterion for statistical significance was p < 0.05.
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